[go: up one dir, main page]

WO2002024229A1 - Methode de regulation de la formation d'osteoclastes - Google Patents

Methode de regulation de la formation d'osteoclastes Download PDF

Info

Publication number
WO2002024229A1
WO2002024229A1 PCT/JP2001/008245 JP0108245W WO0224229A1 WO 2002024229 A1 WO2002024229 A1 WO 2002024229A1 JP 0108245 W JP0108245 W JP 0108245W WO 0224229 A1 WO0224229 A1 WO 0224229A1
Authority
WO
WIPO (PCT)
Prior art keywords
osteoclast formation
ifn
type
signal
formation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2001/008245
Other languages
English (en)
Japanese (ja)
Inventor
Tadatsugu Taniguchi
Hiroshi Takayanagi
Kozo Nakamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Todai TLO Ltd
Original Assignee
Todai TLO Ltd
Center for Advanced Science and Technology Incubation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Todai TLO Ltd, Center for Advanced Science and Technology Incubation Ltd filed Critical Todai TLO Ltd
Priority to JP2002528299A priority Critical patent/JP4924975B2/ja
Priority to AU2001288095A priority patent/AU2001288095A1/en
Publication of WO2002024229A1 publication Critical patent/WO2002024229A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne une méthode de régulation d'un signal de formation d'ostéoclastes. On a constaté que le processus de formation d'ostéoclastes pouvait être inhibé par activation de la transduction du signal IFN type I. L'activation dudit signal permet de rétro-réguler l'expression de la protéine c-Fos induite par RANKL et, par là même, d'inhiber la formation d'ostéoclastes. IFN type I (IFN-α et IFN-β) ont pour effet d'inhiber selon la dose la formation des ostéoclastes. Il apparaît qu'un signal induit par Sta I et IFR-9 est important dans l'inhibition de la formation d'ostéoclastes par IFN type I. On dispose ainsi d'une nouvelle stratégie thérapeutique contre des maladies liées à des déréglements osseux en rapport avec l'arthrite auto-immune.
PCT/JP2001/008245 2000-09-21 2001-09-21 Methode de regulation de la formation d'osteoclastes Ceased WO2002024229A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2002528299A JP4924975B2 (ja) 2000-09-21 2001-09-21 破骨細胞形成を制御する方法
AU2001288095A AU2001288095A1 (en) 2000-09-21 2001-09-21 Method of regulating osteoclast formation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2000286353 2000-09-21
JP2000-286353 2000-09-21
JP2001186372 2001-06-20
JP2001-186372 2001-06-20

Publications (1)

Publication Number Publication Date
WO2002024229A1 true WO2002024229A1 (fr) 2002-03-28

Family

ID=26600382

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/008245 Ceased WO2002024229A1 (fr) 2000-09-21 2001-09-21 Methode de regulation de la formation d'osteoclastes

Country Status (3)

Country Link
JP (1) JP4924975B2 (fr)
AU (1) AU2001288095A1 (fr)
WO (1) WO2002024229A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006068133A1 (fr) * 2004-12-21 2006-06-29 National University Corporation NARA Institute of Science and Technology Procede de suppression de l’expression de nfat2
WO2012050884A3 (fr) * 2010-09-28 2012-07-19 President And Fellows Of Harvard College Glycosides cardiaques qui sont de puissants inhibiteurs de l'expression du gène de l'interféron bêta
WO2023024339A1 (fr) * 2021-08-23 2023-03-02 中国科学院深圳先进技术研究院 Utilisation du facteur rankl dérivé des os dans la préparation d'un médicament ou d'une composition pharmaceutique pour réguler l'homéostasie du système nerveux central
CN117138038A (zh) * 2023-09-21 2023-12-01 北京大学 一种预防、治疗或缓解椎体后纵韧带骨化症的药物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07215893A (ja) * 1994-02-04 1995-08-15 Hiroyo Morii 骨量増加剤
WO1997004799A1 (fr) * 1995-07-25 1997-02-13 Toray Industries, Inc. Remede contre les maladies osseuses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07215893A (ja) * 1994-02-04 1995-08-15 Hiroyo Morii 骨量増加剤
WO1997004799A1 (fr) * 1995-07-25 1997-02-13 Toray Industries, Inc. Remede contre les maladies osseuses

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006068133A1 (fr) * 2004-12-21 2006-06-29 National University Corporation NARA Institute of Science and Technology Procede de suppression de l’expression de nfat2
WO2012050884A3 (fr) * 2010-09-28 2012-07-19 President And Fellows Of Harvard College Glycosides cardiaques qui sont de puissants inhibiteurs de l'expression du gène de l'interféron bêta
WO2023024339A1 (fr) * 2021-08-23 2023-03-02 中国科学院深圳先进技术研究院 Utilisation du facteur rankl dérivé des os dans la préparation d'un médicament ou d'une composition pharmaceutique pour réguler l'homéostasie du système nerveux central
CN117138038A (zh) * 2023-09-21 2023-12-01 北京大学 一种预防、治疗或缓解椎体后纵韧带骨化症的药物

Also Published As

Publication number Publication date
JPWO2002024229A1 (ja) 2004-01-29
AU2001288095A1 (en) 2002-04-02
JP4924975B2 (ja) 2012-04-25

Similar Documents

Publication Publication Date Title
EP1273298A3 (fr) Ritonavir en combinaison avec un inhibiteur de la protéase du VIH additionnel pour le traitement du SIDA
WO2002068470A3 (fr) Gene induit par l'interferon alpha
WO2004010937A3 (fr) Methode de traitement du cancer
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
MXPA04005790A (es) Compuestos y usos de los mismos para reducir la actividad de la lipasa sensible a la hormona.
WO2004006853A3 (fr) Traitement et prevention a l'aide d'agents fixant 4-1bb
FI954580A7 (fi) HIV-proteaasin estäjiä farmaseuttisissa yhdistelmissä käytettäväksi AIDSin hoitoon
WO2003062273A3 (fr) Traitement medical
WO2001064889A3 (fr) CONCEPTION ET DECOUVERTE DE VARIANTS DU TNF-α A BASE DE PROTEINES DESTINES AU TRAITEMENT DES PATHOLOGIES LIEES AU TNF-$g(a)
CA2469343A1 (fr) Combinaison d'inhibiteurs de protease dependant du cytochrome p450
WO2003078430A8 (fr) Amides d'acide acetique et propionique
TW200602073A (en) Use of protein hydrolysates for the manufacture of a medicament for prophylaxis and/or treatment of a DPP-IV mediated condition
WO2002005848A3 (fr) Utilisation d'inhibiteurs de cox-2 pour le traitement et la prevention de troubles oculaires a mediation cox-2
WO2004006912A3 (fr) Combinaison d'un inhibiteur carboxylique allosterique de metalloproteinase-13 de matrice et de celecoxibe ou de valdecoxibe
WO2002024229A1 (fr) Methode de regulation de la formation d'osteoclastes
FI960850A7 (fi) Kinoksaliinien käyttö proteaasi-inhibiittoreihin yhdistettyinä lääkkeeksi AIDS:in ja/tai HIV-tartuntojen hoitamiseksi
WO2002024228A1 (fr) Méthode de régulation de la formation d'ostéoclastes
WO2004016741A3 (fr) Inhibiteurs de la prenylation contenant du dimethylcyclobutane, leurs methodes de synthese et leur utilisation
AU2003206945A1 (en) Use of proteinase inhibitors in the treatment of autoimmune diseases
WO2001010893A3 (fr) Antagonistes de l'interleukine-16
WO2002090552A3 (fr) Utilisation de polypeptides, ou d'acides nucleiques les codant, d'une 2'-5'-oligoadenylate synthetase et/ou d'arnsel pour le diagnostic, la prevention ou le traitement de cicatrisation de plaies, et leur utilisation afin d'identifier des substances actives sur le plan pharmacologique
AU2003297399A1 (en) Nucleic acids encoding antifungal drug targets and methods of use
WO2001070953A3 (fr) Traitement de la restenose
WO2003011263A3 (fr) Utilisation d'un sel de lactate pour le traitement et la prophylaxie de l'atherosclerose
AU2003291524A1 (en) Treatment of ophthalmic conditions with kpv and kpv dimers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002528299

Country of ref document: JP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase